Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY96O3)

Drug Name

acelarin Drug Info

Synonyms

NUC-1031

Indication

Disease Entry	ICD 11	Status	REF
Biliary tract cancer	2C17	Phase 3	[1]
Ovarian cancer	2C73	Phase 2	[2]
Alzheimer disease	8A20	Phase 1	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA synthesis (DNA synth)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nelarabine	DMB6VEG	leukaemia	2A60-2B33	Approved	[4]
Glufosfamide	DMEFCTP	Pancreatic cancer	2C10	Phase 3	[2]
FF-10502-01	DMX5290	Lymphoma	2A80-2A86	Phase 1	[2]
TAR-200	DMSQZEP	Bladder cancer	2C94	Phase 1	[2]
CLOTURIN	DMKFMYR	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[5]
EPD-clofarabine	DM149HL	Solid tumour/cancer	2A00-2F9Z	Terminated	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04163900) Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol. 2012 Nov;4(6):341-6.
4	Nelarabine. Drugs. 2008;68(4):439-47.
5	Inhibition of biosynthetic processes in P388 and Ehrlich ascites cells by cloturin. Drugs Exp Clin Res. 1988;14(9):575-80.
6	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.